<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font18 { font-size : 18; } .font19 { font-size : 19; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font28 { font-size : 28; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">NCT </span>
   <span class="font28">Phase </span>
   <span class="font19">Recruiting </span>
   <span class="font19">recruiting </span>
   <span class="font18">[]. </span>
   <span class="font16">USA </span>
   <span class="font15">COVID- </span>
   <span class="font15">cells </span>
   <span class="font14">treatment </span>
   <span class="font14">III </span>
   <span class="font14">patients </span>
   <span class="font13">China </span>
   <span class="font13">coronavirus </span>
   <span class="font13">cell </span>
   <span class="font13">clinical </span>
   <span class="font13">SARS-CoV- </span>
   <span class="font13">viral </span>
   <span class="font12">human </span>
   <span class="font12">immune </span>
   <span class="font12">lung </span>
   <span class="font12">respiratory </span>
   <span class="font12">therapeutic </span>
   <span class="font12">{border-style </span>
   <span class="font12">severe </span>
   <span class="font11">II/III </span>
   <span class="font11">infection </span>
   <span class="font11">px;} </span>
   <span class="font11">virus </span>
   <span class="font11">#ffffff;} </span>
   <span class="font11">antibodies </span>
   <span class="font11">disease </span>
   <span class="font11">indicated </span>
   <span class="font11">I/II </span>
   <span class="font11">Spain </span>
   <span class="font11">cytokine </span>
   <span class="font11">monoclonal </span>
   <span class="font11">novel </span>
   <span class="font11">SARS </span>
   <span class="font11">acute </span>
   <span class="font11">ACE </span>
   <span class="font11">France </span>
   <span class="font11">Med </span>
   <span class="font11">effects </span>
   <span class="font11">inflammatory </span>
   <span class="font11">potential </span>
   <span class="font11">syndrome </span>
   <span class="font11">inhibit </span>
   <span class="font11">number </span>
   <span class="font11">antibody </span>
   <span class="font11">protease </span>
   <span class="font11">stem </span>
   <span class="font11">therapy </span>
   <span class="font11">Infect </span>
   <span class="font11">Italy </span>
   <span class="font11">RNA </span>
   <span class="font11">convalescent </span>
   <span class="font11">effective </span>
   <span class="font11">host </span>
   <span class="font11">infections </span>
   <span class="font11">protein </span>
   <span class="font11">vs. </span>
   <span class="font10">Dis </span>
   <span class="font10">MSC </span>
   <span class="font10">[], </span>
   <span class="font10">cytokines </span>
   <span class="font10">inflammation </span>
   <span class="font10">inhibitors </span>
   <span class="font10">prevent </span>
   <span class="font10">receptor </span>
   <span class="font10">response </span>
   <span class="font10">treat </span>
   <span class="font10">used </span>
   <span class="font10">However, </span>
   <span class="font10">Res </span>
   <span class="font10">Wang </span>
   <span class="font10">chloroquine </span>
   <span class="font10">increased </span>
   <span class="font10">infection. </span>
   <span class="font10">px; </span>
   <span class="font10">responses </span>
   <span class="font10">using </span>
   <span class="font10">vaccination </span>
   <span class="font10">{font-family </span>
   <span class="font10">BCG </span>
   <span class="font10">COVID-: </span>
   <span class="font10">Cell </span>
   <span class="font10">Chen </span>
   <span class="font10">Egypt </span>
   <span class="font10">Iran </span>
   <span class="font10">MSCs </span>
   <span class="font10">Sci </span>
   <span class="font10">Therefore, </span>
   <span class="font10">[â€"]. </span>
   <span class="font10">anti-inflammatory </span>
   <span class="font10">antiviral </span>
   <span class="font10">enzyme </span>
   <span class="font10">font-size </span>
   <span class="font10">immunotherapy </span>
   <span class="font10">including </span>
   <span class="font10">mesenchymal </span>
   <span class="font10">mortality </span>
   <span class="font10">neutralizing </span>
   <span class="font10">new </span>
   <span class="font10">plasma </span>
   <span class="font10">pneumonia </span>
   <span class="font10">reported </span>
   <span class="font10">role </span>
   <span class="font10">serum </span>
   <span class="font10">shown </span>
   <span class="font10">stromal </span>
   <span class="font10">trials </span>
   <span class="font10">use </span>
   <span class="font10">vaccine </span>
   <span class="font10">ARDS </span>
   <span class="font10">Available </span>
   <span class="font10">COVID-. </span>
   <span class="font10">East </span>
   <span class="font10">HIV </span>
   <span class="font10">Immunol </span>
   <span class="font10">Institute </span>
   <span class="font10">LIF </span>
   <span class="font10">Medical </span>
   <span class="font10">Middle </span>
   <span class="font10">Research </span>
   <span class="font10">SARS-CoV </span>
   <span class="font10">Wuhan, </span>
   <span class="font10">angiotensin-converting </span>
   <span class="font10">approaches </span>
   <span class="font10">combination </span>
   <span class="font10">decreased </span>
   <span class="font10">double; </span>
   <span class="font10">drugs </span>
   <span class="font10">hydroxychloroquine </span>
   <span class="font10">important </span>
   <span class="font10">individuals </span>
   <span class="font10">infected </span>
   <span class="font10">lopinavir/ritonavir </span>
   <span class="font10">medRxiv </span>
   <span class="font10">registered </span>
   <span class="font10">showed </span>
   <span class="font10">storm </span>
   <span class="font10">strategy </span>
   <span class="font10">tocilizumab </span>
   <span class="font10">Acad </span>
   <span class="font10">China. </span>
   <span class="font10">Enrolling </span>
   <span class="font10">IL- </span>
   <span class="font10">IL-, </span>
   <span class="font10">Liu </span>
   <span class="font10">Moreover, </span>
   <span class="font10">alveolar </span>
   <span class="font10">animal </span>
   <span class="font10">beneficial </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">cases </span>
   <span class="font10">cells, </span>
   <span class="font10">corticosteroids </span>
   <span class="font10">efficacy </span>
   <span class="font10">entry </span>
   <span class="font10">exhaustion </span>
   <span class="font10">factor </span>
   <span class="font10">immunomodulatory </span>
   <span class="font10">improved </span>
   <span class="font10">inhibitor </span>
   <span class="font10">inhibitory </span>
   <span class="font10">injury </span>
   <span class="font10">interferon </span>
   <span class="font10">invitation </span>
   <span class="font10">mAbs </span>
   <span class="font10">patient </span>
   <span class="font10">patients. </span>
   <span class="font10">people </span>
   <span class="font10">potent </span>
   <span class="font10">recombinant </span>
   <span class="font10">remdesivir </span>
   <span class="font10">replication </span>
   <span class="font10">results </span>
   <span class="font10">severity </span>
   <span class="font10">solid; </span>
   <span class="font10">soluble </span>
   <span class="font10">studies </span>
   <span class="font10">study </span>
   <span class="font10">systemic </span>
   <span class="font10">viruses </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">Brazil </span>
   <span class="font10">Favipiravir </span>
   <span class="font10">Hydroxychloroquine, </span>
   <span class="font10">MERS </span>
   <span class="font10">MSC; </span>
   <span class="font10">Medicine, </span>
   <span class="font10">Monoclonal </span>
   <span class="font10">Natl </span>
   <span class="font10">Potential </span>
   <span class="font10">Sciences, </span>
   <span class="font10">Ther </span>
   <span class="font10">University </span>
   <span class="font10">Virol </span>
   <span class="font10">adoptive </span>
   <span class="font10">azithromycin </span>
   <span class="font10">bioRxiv </span>
   <span class="font10">bold </span>
   <span class="font10">compared </span>
   <span class="font10">considered </span>
   <span class="font10">courier; </span>
   <span class="font10">distress </span>
   <span class="font10">effect </span>
   <span class="font10">effectively </span>
   <span class="font10">em; </span>
   <span class="font10">essential </span>
   <span class="font10">excessive </span>
   <span class="font10">form </span>
   <span class="font10">function </span>
   <span class="font10">grid.. </span>
   <span class="font10">high </span>
   <span class="font10">immunity </span>
   <span class="font10">improve </span>
   <span class="font10">infection, </span>
   <span class="font10">inflammation, </span>
   <span class="font10">innate </span>
   <span class="font10">major </span>
   <span class="font10">management </span>
   <span class="font10">mechanisms </span>
   <span class="font10">neutralization </span>
   <span class="font10">open-label </span>
   <span class="font10">phase </span>
   <span class="font10">play </span>
   <span class="font10">progression </span>
   <span class="font10">pt;} </span>
   <span class="font10">recovered </span>
   <span class="font10">reduced </span>
   <span class="font10">spike </span>
   <span class="font10">targets </span>
   <span class="font10">tissue </span>
   <span class="font10">transfer </span>
   <span class="font10">trial </span>
   <span class="font10">vitro </span>
  </p>
 </body>
</html>
